The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock

References

• Jentzer JC, Vallabhajosyula S, Khanna AK, et al. Management of refractory vasodilatory shock. Chest. 2018;154(2):416–426.
   Google Scholar
• Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care. 2020;24(1):36.
   Google Scholar
• Lambden S, Creagh-Brown BC, Hunt J, et al. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174.
   Google Scholar
• Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345(8):588–595.
   Google Scholar
• Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21–30.
   Google Scholar
• Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45(11):1503–1517.
   Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063–e143.
   Google Scholar
• Guarracino F, Habicher M, Treskatsch S, et al. Vasopressor therapy in cardiac surgery-an experts’ consensus statement. J Cardiothorac Vasc Anesth. 2021;35(4):1018–1029.
   Google Scholar
• Miller AJ, Shifrin A, Kaplan BM, et al. Arterenol in treatment of shock. J Am Med Assoc. 1953;152(13):1198–1201.
   Google Scholar
• Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10(8):e0129305.
   Google Scholar
• Vasu TS, Cavallazzi R, Hirani A, et al. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med. 2012;27(3):172–178.
   Google Scholar
• Ruslan MA, Baharuddin KA, Noor NM, et al. Norepinephrine in septic shock: a systematic review and meta-analysis. West J Emerg Med. 2021;22(2):196–203.
   Google Scholar
• Roberts RJ, Miano TA, Hammond DA, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med. 2020;48(10):1445–1453.
   Google Scholar
• Permpikul C, Tongyoo S, Viarasilpa T, et al. Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med. 2019;199(9):1097–1105.
   Google Scholar
• Bai X, Yu W, Ji W, et al. Early versus delayed administration of norepinephrine in patients with septic shock. Crit Care. 2014;18(5):532.
   Google Scholar
• Belletti A, Nagy A, Sartorelli M, et al. Effect of continuous epinephrine infusion on survival in critically Ill patients: a meta-analysis of randomized trials. Crit Care Med. 2020;48(3):398–405.
   Google Scholar
• Zhu Y, Yin H, Zhang R, et al. The effect of dobutamine vs milrinone in sepsis: a big data, real-world study. Int J Clin Pract. 2021;75(11):e14689.
   Google Scholar
• Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. Rev Bras Ter Intensiva. 2017;29(4):490–498.
   Google Scholar
• Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–430.
   Google Scholar
• Chawla LS, Russell JA, Bagshaw SM, et al. Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017;19(1):43–49.
   Google Scholar
• Russell JA, Gordon AC, Williams MD, et al. Vasopressor therapy in the intensive care unit. Semin Respir Crit Care Med. 2021;42(1):59–77.
   Google Scholar
• Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25(8):1279–1282.
   Google Scholar
• Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy. 2004;24(8):1002–1012.
   Google Scholar
• Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576–582.
   Google Scholar
• Lauzier F, Levy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med. 2006;32(11):1782–1789.
   Google Scholar
• Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology. 2017;126(1):85–93.
   Google Scholar
• Sacha GL, Lam SW, Wang L, et al. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med. 2022;50(4):614–623.
   Google Scholar
• Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial. Crit Care Med. 2019;47(12):1743–1750.
   Google Scholar
• Erwin BL, Denaburg MA, Barker AB, et al. Evaluation of vasopressin for septic shock in patients on chronic renin-angiotensin-aldosterone system inhibitors. Crit Care Med. 2017;45(12):e1226–e32.
   Google Scholar
• Singer M. Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol. 2008;22(2):359–368.
   Google Scholar
• Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828.
   Google Scholar
• Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26 Suppl 1:109–114.
   Google Scholar
• Lange M, Ertmer C, Westphal M. Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med. 2008;34(5):821–832.
   Google Scholar
• O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet. 2002;359(9313):1209–1210.
   Google Scholar
• Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med. 2004;30(3):477–480.
   Google Scholar
• Svoboda P, Scheer P, Kantorova I, et al. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology. 2012;59(116):1043–1047.
   Google Scholar
• Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res. 2016;200(1):274–282.
   Google Scholar
• Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth. 2008;100(4):494–503.
   Google Scholar
• Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13(4):R130.
   Google Scholar
• Albanese J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005;33(9):1897–1902.
   Google Scholar
• Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017;37(4):552–561.
   Google Scholar
• Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med. 2018;44(11):1816–1825.
   Google Scholar
• Huang P, Guo Y, Li B, et al. Terlipressin versus norepinephrine for septic shock: a systematic review and meta-analysis. Front Pharmacol. 2019;10:1492.
   Google Scholar
• He X, Su F, Taccone FS, et al. A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med. 2016;44(1):23–31.
   Google Scholar
• Russell JA, Vincent JL, Kjolbye AL, et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017;21(1):213.
   Google Scholar
• Laterre PF, Berry SM, Blemings A, et al. Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA. 2019;322(15):1476–1485.
   Google Scholar
• Nakamura K, Nakano H, Naraba H, et al. Vasopressin loading for refractory septic shock: a preliminary analysis of a case series. Front Med (Lausanne). 2021;8:644195.
   Google Scholar
• Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–887.
   Google Scholar
• Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–518.
   Google Scholar
• Antcliffe DB, Burnham KL, Al-Beidh F, et al. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980–986.
   Google Scholar
• Webb AJ, Seisa MO, Nayfeh T, et al. Vasopressin in vasoplegic shock: a systematic review. World J Crit Care Med. 2020;9(5):88–98.
   Google Scholar
• Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019;45(6):844–855.
   Google Scholar
• Yao RQ, Xia DM, Wang LX, et al. Clinical efficiency of vasopressin or its analogs in comparison with catecholamines alone on patients with septic shock: a systematic review and meta-analysis. Front Pharmacol. 2020;11:563.
   Google Scholar
• Jiang L, Sheng Y, Feng X, et al. The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis. Crit Care. 2019;23(1):91.
   Google Scholar
• Serpa Neto A, Nassar AP, Cardoso SO, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16(4):R154.
   Google Scholar
• Belletti A, Musu M, Silvetti S, et al. Non-adrenergic vasopressors in patients with or at risk for vasodilatory shock. A systematic review and meta-analysis of randomized trials. PLoS One. 2015;10(11):e0142605.
   Google Scholar
• Dunser MW, Bouvet O, Knotzer H, et al. Vasopressin in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2018;32(5):2225–2232.
   Google Scholar
• Wu Z, Zhang S, Xu J, et al. Norepinephrine vs vasopressin: which vasopressor should be discontinued first in septic shock? A meta-analysis. Shock. 2020;53(1):50–57.
   Google Scholar
• Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003;31(5):1394–1398.
   Google Scholar
• van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest. 2003;124(6):2256–2260.
   Google Scholar
• Gordon AC, Wang N, Walley KR, et al. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest. 2012;142(3):593–605.
   Google Scholar
• McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA. 2018;319(18):1889–1900.
   Google Scholar
• Sacha GL, Kiser TH, Wright GC, et al. Association between vasopressin rebranding and utilization in patients with septic shock. Crit Care Med. 2022;50(4):644–654.
   Google Scholar
• Senatore F, Balakumar P, Jagadeesh G. Dysregulation of the renin-angiotensin system in septic shock: mechanistic insights and application of angiotensin II in clinical management. Pharmacol Res. 2021;174:105916.
   Google Scholar
• Wakefield BJ, Busse LW, Khanna AK. Angiotensin II in Vasodilatory Shock. Crit Care Clin. 2019;35(2):229–245.
   Google Scholar
• Jadhav AP, Sadaka FG. Angiotensin II in septic shock. Am J Emerg Med. 2019;37(6):1169–1174.
   Google Scholar
• Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension. 2001;38(6):1246–1249.
   Google Scholar
• Heavner MS, McCurdy MT, Mazzeffi MA, et al. Angiotensin II and vasopressin for vasodilatory shock: a critical appraisal of catecholamine-sparing strategies. J Intensive Care Med. 2021;36(6):635–645.
   Google Scholar
• Rysz S, Al-Saadi J, Sjostrom A, et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nat Commun. 2021;12(1):2417.
   Google Scholar
• Wieruszewski PM, Radosevich MA, Kashani KB, et al. Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock. J Cardiothorac Vasc Anesth. 2019;33(11):3080–3084.
   Google Scholar
• Del Greco F. Clinical experience with angiotensin II in the treatment of shock. JAMA. 1961;178(10):994–999.
   Google Scholar
• Derrick JR, Anderson JR, Roland BJ. Adjunctive use of a biologic pressor agent, angiotensin, in management of shock. Circulation. 1962;25:263–267.
   Google Scholar
• Ames RP, Borkowski AJ, Sicinski AM, et al. Prolonged infusions of angiotensin Ii and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171–1186.
   Google Scholar
• Cohn JN, Luria MH. Studies in clinical shock and hypotension. Ii. Hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44:1494–1504.
   Google Scholar
• Thomas VL, Nielsen MS. Administration of angiotensin II in refractory septic shock. Crit Care Med. 1991;19(8):1084–1086.
   Google Scholar
• Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;346(8990):1604.
   Google Scholar
• Whiteley SM, Dade JP. Treatment of hypotension in septic shock. Lancet. 1996;347(9001):622.
   Google Scholar
• Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child. 2000;82(5):388–389.
   Google Scholar
• Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165–1168.
   Google Scholar
• Desachy A, Normand S, Francois B, et al. [Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II]. Presse Med. 2000;29(13):696–698.
   Google Scholar
• Newby DE, Lee MR, Gray AJ, et al. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40(1):103–104.
   Google Scholar
• Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.
   Google Scholar
• Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949–957.
   Google Scholar
• Ham KR, Boldt DW, McCurdy MT, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9(1):63.
   Google Scholar
• Szerlip H, Bihorac A, Chang S, et al. Effect of disease severity on survival in patients receiving angiotensin II for vasodilatory shock. Crit Care Med. 2018;46(1):3.
   Google Scholar
• AT BL, Gong M, Thompson BT, et al. Outcomes in patients with acute respiratory syndrome receiving angiotensin II for vasodilatory shock. 38th International Symposium on Intensive Care and Emergency Medicine; 2018 Mar 29; Brussels, Belgium; 2018.
   Google Scholar
• Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24(1):43.
   Google Scholar
• Bellomo R, Forni LG, Busse LW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202(9):1253–1261.
   Google Scholar
• Senatore F, Jagadeesh G, Rose M, et al. FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock. Am J Cardiovasc Drugs. 2019;19(1):11–20.
   Google Scholar
• Smith SE, Newsome AS, Guo Y, et al. A multicenter observational cohort study of angiotensin II in shock. J Intensive Care Med. 2022;37(1):75–82.
   Google Scholar
• Wieruszewski PM, Wittwer ED, Kashani KB, et al. Angiotensin II infusion for shock: a multicenter study of postmarketing use. Chest. 2021;159(2):596–605.
   Google Scholar
• Leisman DE, Mastroianni F, Fisler G, et al. Physiologic response to angiotensin II treatment for coronavirus disease 2019-induced vasodilatory shock: a retrospective matched cohort study. Crit Care Explor. 2020;2(10):e0230.
   Google Scholar
• Quan M, Cho N, Bushell T, et al. Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor. 2022;4(1):e0623.
   Google Scholar
• Datt V, Wadhhwa R, Sharma V, et al. Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management. J Card Surg. 2021;36(10):3749–3760.
   Google Scholar
• Chow JH, Galvagno SM Jr., Tanaka KA, et al. When all else fails: novel use of angiotensin ii for vasodilatory shock: a case report. A A Pract. 2018;11(7):175–180.
   Google Scholar
• Chatterjee S, Preventza O, Mousavi MC, et al. Successful use of angiotensin II for vasoplegia after thoracoabdominal aortic aneurysm repair. JTCVS Tech. 2020;4:72–75.
   Google Scholar
• Trethowan B, Michaud CJ, Fifer S. Use of angiotensin II in severe vasoplegia after left pneumonectomy requiring cardiopulmonary bypass: a renin response analysis. Crit Care Med. 2020;48(10):e912–e5.
   Google Scholar
• Wieruszewski PM, Sims CR, Daly RC, et al. Use of angiotensin II for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology. J Cardiothorac Vasc Anesth. 2019;33(8):2366–2367.
   Google Scholar
• Cutler NS, Rasmussen BM, Bredeck JF, et al. Angiotensin II for critically Ill patients with shock after heart transplant. J Cardiothorac Vasc Anesth. 2021;35(9):2756–2762.
   Google Scholar
• Sovic W, Mathew C, Blough B, et al. Angiotensin II: a multimodal approach to vasoplegia in a cardiac setting. Methodist DeBakey Cardiovasc J. 2021;17(4):98–101.
   Google Scholar
• Klijian A, Khanna AK, Reddy VS, et al. Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: a post-hoc analysis of angiotensin II for the treatment of high-output shock (ATHOS-3) study. J Cardiothorac Vasc Anesth. 2021;35(1):51–58.
   Google Scholar
• Papazisi O, Palmen M, Danser AHJ. The use of angiotensin ii for the treatment of post-cardiopulmonary bypass vasoplegia. Cardiovasc Drugs Ther. 2020;36:739–748.
   Google Scholar
• Running K, Weinberg D, Trudo W, et al. Intraoperative use of angiotensin II for severe vasodilatory shock during liver transplantation: a case report. A A Pract. 2021;15(2):e01402.
   Google Scholar
• Chow JH, Strauss E, Mazzeffi MA. Angiotensin II and vasoplegia in cardiac surgery: paradigm changer or costly contender? J Cardiothorac Vasc Anesth. 2021;35(1):59–60.
   Google Scholar
• Balsam LB. Commentary: angiotensin II for vasoplegia: a desperate measure for desperate times. JTCVS Tech. 2020;4:77–78.
   Google Scholar
• Nicholson G, Zeng F, Lee C, et al. Giapreza for the treatment of severe distributive shock in the intensive care unit: a us cost-effectiveness analysis. Value Health. 2018;21:S60–S.
   Google Scholar
• Busse LW, Nicholson G, Nordyke RJ, et al. Angiotensin II for the treatment of distributive shock in the intensive care unit: a US cost-effectiveness analysis. Int J Technol Assess Health Care. 2020;36(2):145–151.
   Google Scholar
• Anyanwu P, Wanat M, Thornton JD, et al. PDG22 a decision analysis of adding angiotensin II to renal replacement therapy to treat patients with acute kidney injury and vasodilatory shock. Value Health. 2019;22:S166–S.
   Google Scholar
• Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285–1294.
   Google Scholar
• Puntillo F, Giglio M, Pasqualucci A, et al. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther. 2020;37(9):3692–3706.
   Google Scholar
• Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010;22(4):275–280.
   Google Scholar
• Memis D, Karamanlioglu B, Yuksel M, et al. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002;30(6):755–762.
   Google Scholar
• Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001;29(10):1860–1867.
   Google Scholar
• Senthilnathan M, Cherian A, Balachander H, et al. Role of methylene blue in the maintenance of postinduction hemodynamic status in patients with perforation peritonitis: a pilot study. Anesth Essays Res. 2017;11(3):665–669.
   Google Scholar
• Ismail R, Awad H, Allam R, et al. Methylene blue versus vasopressin analog for refractory septic shock in the preterm neonate: a randomized controlled trial. J Neonatal Perinatal Med. 2021. DOI:10.3233/NPM-210824
   Google Scholar
• Porizka M, Kopecky P, Dvorakova H, et al. Methylene blue administration in patients with refractory distributive shock - a retrospective study. Sci Rep. 2020;10(1):1828.
   Google Scholar
• Bitterman Y, Hubara E, Hadash A, et al. Methylene Blue Administration for Distributive Shock States in Critically Ill Children. Isr Med Assoc J. 2020;22(7):404–408.
   Google Scholar
• Weiner MM, Lin HM, Danforth D, et al. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth. 2013;27(6):1233–1238.
   Google Scholar
• Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 2002;30(10):2271–2277.
   Google Scholar
• Andresen M, Dougnac A, Hernandez G, et al. [Inhibition of the nitric oxide pathway in refractory septic shock]. Rev Med Chil. 1996;124(4):442–447.
   Google Scholar
• Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, et al. Methylene blue increases myocardial function in septic shock. Crit Care Med. 1995;23(8):1363–1370.
   Google Scholar
• Park BK, Shim TS, Lim CM, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005;20(2):123–128.
   Google Scholar
• Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23(2):259–264.
   Google Scholar
• Jaiswal A, Kumar M, Silver E. Extended continuous infusion of methylene blue for refractory septic shock. Indian J Crit Care Med. 2020;24(3):206–207.
   Google Scholar
• Ortoleva J, Roberts RJ, Devine LT, et al. Methylene blue for vasoplegia during extracorporeal membrane oxygenation support. J Cardiothorac Vasc Anesth. 2021;35(9):2694–2699.
   Google Scholar
• Harding P, Nicholas T, Kassel C. The use of methylene blue during liver transplantation for vasoplegia. Case Rep Anesthesiol. 2021;2021:6610754.
   Google Scholar
• Gachot B, Bedos JP, Veber B, et al. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21(12):1027–1031.
   Google Scholar
• Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999;32(12):1505–1513.
   Google Scholar
• Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care. 1998;13(4):164–168.
   Google Scholar
• Hamidi-Alamdari D, Hafizi-Lotfabadi S, Bagheri-Moghaddam A, et al. Methylene blue for treatment of hospitalized Covid-19 patients: a randomized, controlled, open-label clinical trial, phase 2. Rev Invest Clin. 2021;73(3):190–198.
   Google Scholar
• Naoum EE, Dalia AA, Roberts RJ, et al. Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study. BMC Anesthesiol. 2022;22(1):199.
   Google Scholar
• Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013;15(1):42–48.
   Google Scholar
• Zhang X, Gao Y, Pan P, et al. [Methylene blue in the treatment of vasodilatory shock: a meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29(11):982–987.
   Google Scholar
• Hohlfelder B, Douglas A, Wang L, et al. Association of methylene blue dosing with hemodynamic response for the treatment of vasoplegia. J Cardiothorac Vasc Anesth. 2022;36:3543–3550.
   Google Scholar
• Kofler O, Simbeck M, Tomasi R, et al. Early use of methylene blue in vasoplegic syndrome: a 10-year propensity score-matched cohort study. J Clin Med. 2022;11(4):1121.
   Google Scholar
• Patel JJ, Venegas-Borsellino C, Willoughby R, et al. High-dose vitamin B12 in vasodilatory shock: a narrative review. Nutr Clin Pract. 2019;34(4):514–520.
   Google Scholar
• Gerth K, Ehring T, Braendle M, et al. Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile. Clin Toxicol (Phila). 2006;44 Suppl 1:29–36.
   Google Scholar
• Shapeton AD, Mahmood F, Ortoleva JP. Hydroxocobalamin for the treatment of vasoplegia: a review of current literature and considerations for use. J Cardiothorac Vasc Anesth. 2019;33(4):894–901.
   Google Scholar
• Uhl W, Nolting A, Golor G, et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila). 2006;44 Suppl 1:17–28.
   Google Scholar
• Uhl W, Nolting A, Gallemann D, et al. Changes in blood pressure after administration of hydroxocobalamin: relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers. Clin Toxicol (Phila). 2008;46(6):551–559. discussion 76-7.
   Google Scholar
• Ritter LA, Maldarelli M, McCurdy MT, et al. Effects of a single bolus of hydroxocobalamin on hemodynamics in vasodilatory shock. J Crit Care. 2022;67:66–71.
   Google Scholar
• Armour S, Armour TK, Joppa WR, et al. Use of hydroxocobalamin (vitamin B12a) in patients with vasopressor refractory hypotension after cardiopulmonary bypass: a case series. Anesth Analg. 2019;129(1):e1–e4.
   Google Scholar
• Roderique JD, VanDyck K, Holman B, et al. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg. 2014;97(5):1785–1786.
   Google Scholar
• An SS, Henson CP, Freundlich RE, et al. Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation. Am J Transplant. 2018;18(6):1552–1555.
   Google Scholar
• Woehlck HJ, Boettcher BT, Lauer KK, et al. Hydroxocobalamin for vasoplegic syndrome in liver transplantation: restoration of blood pressure without vasospasm. A A Case Rep. 2016;7(12):247–250.
   Google Scholar
• Boettcher BT, Woehlck HJ, Reck SE, et al. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation. J Cardiothorac Vasc Anesth. 2017;31(4):1381–1384.
   Google Scholar
• Cai Y, Mack A, Ladlie BL, et al. The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant vasoplegic syndrome in cardiac surgery. Ann Card Anaesth. 2017;20(4):462–464.
   Google Scholar
• Peyko V, Finamore M. Use of intravenous hydroxocobalamin without methylene blue for refractory vasoplegic syndrome after cardiopulmonary bypass. Am J Case Rep. 2021;22:e930890.
   Google Scholar
• Zundel MT, Feih JT, Rinka JRG, et al. Hydroxocobalamin with or without methylene blue may improve fluid balance in critically Ill patients with vasoplegic syndrome after cardiac surgery: a report of two cases. J Cardiothorac Vasc Anesth. 2018;32(1):452–457.
   Google Scholar
• Feih JT, Rinka JRG, Zundel MT. Methylene blue monotherapy compared with combination therapy with hydroxocobalamin for the treatment of refractory vasoplegic syndrome: a retrospective cohort study. J Cardiothorac Vasc Anesth. 2019;33(5):1301–1307.
   Google Scholar
• Vollmer N, Wieruszewski PM, Martin N, et al. Predicting the response of hydroxocobalamin in postoperative vasoplegia in recipients of cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2022;36(8 Pt B):2908–2916.
   Google Scholar
• Burnes ML, Boettcher BT, Woehlck HJ, et al. Hydroxocobalamin as a rescue treatment for refractory vasoplegic syndrome after prolonged cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2017;31(3):1012–1014.
   Google Scholar
• Charles FG, Murray LJ, Giordano C, et al. Vitamin B12 for the treatment of vasoplegia in cardiac surgery and liver transplantation: a narrative review of cases and potential biochemical mechanisms. Can J Anaesth. 2019;66(12):1501–1513.
   Google Scholar
• Weinberg D, Running K, Kalarickal PL, et al. Use of intravenous hydroxocobalamin for vasoplegic syndrome in simultaneous liver-kidney transplant: a case report. Transplant Proc. 2021;53(4):1300–1302.
   Google Scholar
• Bebarta VS, Garrett N, Maddry JK, et al. A prospective, randomized trial of intravenous hydroxocobalamin versus noradrenaline or saline for treatment of lipopolysaccharide-induced hypotension in a swine model. Clin Exp Pharmacol Physiol. 2019;46(3):216–225.
   Google Scholar
• Lin Y, Vu TQ. Use of high-dose hydroxocobalamin for septic shock: a case report. A A Pract. 2019;12(9):332–335.
   Google Scholar
• Gerdes HJ, Seelhammer TG, Nei S, et al. Extended duration infusion of hydroxocobalamin for vasoplegic rescue in septic shock. Cureus. 2021;13(2):e13388.
   Google Scholar
• Clifford KM, Madhok J, Murray NM, et al. Rescue of nimodipine-induced refractory vasoplegia with hydroxocobalamin in subarachnoid hemorrhage: a case report. Crit Care Explor. 2020;2(10):e0205.
   Google Scholar
• Tawil JN, Khatib D, Jakobsons JJ, et al. Rainbow after the storm. Br J Anaesth. 2017;118(4):641.
   Google Scholar
• Branco-Ferreira M, Clode MH, Pereira-Barbosa MA, et al. Anaphylactic reaction to hydroxycobalamin. Allergy. 1997;52(1):118–119.
   Google Scholar
• Vidal C, Lorenzo A. Anaphylactoid reaction to hydroxocobalamin with tolerance of cyanocobalamin. Postgrad Med J. 1998;74(877):702.
   Google Scholar
• Sutter M, Tereshchenko N, Rafii R, et al. Hemodialysis complications of hydroxocobalamin: a case report. J Med Toxicol. 2010;6(2):165–167.
   Google Scholar
• Sutter ME, Clarke ME, Cobb J, et al. Blood leak alarm interference by hydroxocobalamin is hemodialysis machine dependent. Clin Toxicol (Phila). 2012;50(10):892–895.
   Google Scholar
• Cheungpasitporn W, Hui J, Kashani KB, et al. High-dose hydroxocobalamin for vasoplegic syndrome causing false blood leak alarm. Clin Kidney J. 2017;10(3):357–362.
   Google Scholar
• Fang F, Zhang Y, Tang J, et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(2):213–223.
   Google Scholar
• Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med. 2018;46(9):1411–1420.
   Google Scholar
• Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019;12:CD002243.
   Google Scholar
• Gibbison B, Lopez-Lopez JA, Higgins JP, et al. Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care. 2017;21(1):78.
   Google Scholar
• Xu R, Wang Q, Huang Y, et al. Do low-dose corticosteroids improve survival or shock reversal from septic shock in adults? Meta-analysis with trial sequential analysis. J Int Med Res. 2018;46(7):2513–2524.
   Google Scholar
• Lyu QQ, Chen QH, Zheng RQ, et al. Effect of low-dose hydrocortisone therapy in adult patients with septic shock: a meta-analysis with trial sequential analysis of randomized controlled trials. J Intensive Care Med. 2020;35(10):971–983.
   Google Scholar
• Bosch NA, Teja B, Wunsch H, et al. Practice patterns in the initiation of secondary vasopressors and adjunctive corticosteroids during septic shock in the United States. Ann Am Thorac Soc. 2021;18(12):2049–2057.
   Google Scholar
• Sato R, Hasegawa D, Prasitlumkum N, et al. Effect of IV high-dose vitamin C on mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2021;49(12):2121–2130.
   Google Scholar
• Jung SY, Lee MT, Baek MS, et al. Vitamin C for >/= 5 days is associated with decreased hospital mortality in sepsis subgroups: a nationwide cohort study. Crit Care. 2022;26(1):3.
   Google Scholar
• Lamontagne F, Masse MH, Menard J, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022;386(25):2387–2398.
   Google Scholar
• Assouline B, Faivre A, Verissimo T, et al. Thiamine, ascorbic acid, and hydrocortisone as a metabolic resuscitation cocktail in sepsis: a meta-analysis of randomized controlled trials with trial sequential analysis. Crit Care Med. 2021;49(12):2112–2120.
   Google Scholar
• Fujii T, Salanti G, Belletti A, et al. Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: a systematic review and a component network meta-analysis. Intensive Care Med. 2022;48(1):16–24.
   Google Scholar
• Sevransky JE, Rothman RE, Hager DN, et al. Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial. JAMA. 2021;325(8):742–750.
   Google Scholar
• Barnes TJ, Hockstein MA, Jabaley CS. Vasoplegia after cardiopulmonary bypass: a narrative review of pathophysiology and emerging targeted therapies. SAGE Open Med. 2020;8:2050312120935466.
   Google Scholar
• Bussard RL, Busse LW. Angiotensin II: a new therapeutic option for vasodilatory shock. Ther Clin Risk Manag. 2018;14:1287–1298.
   Google Scholar
• Chvojka J, Martinkova V, Benes J, et al. Mechanical circulatory support in refractory vasodilatory septic shock: a randomized controlled porcine study. Shock. 2020;53(1):124–131.
   Google Scholar
• Ten Lohuis CC, Burke SC, Jannuzzo CJ, et al. Protocol compliance guiding angiotensin II use in post cardiovascular surgery vasoplegia. Crit Care Explor. 2022;4(5):e0687.
   Google Scholar
• Chawla LS, Ostermann M, Forni L, et al. Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care. 2019;23(1):124.
   Google Scholar